Christopher S Stipp
Overview
Explore the profile of Christopher S Stipp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1325
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Riordan J, Nathanson T, Varzavand A, Hawkins A, Peplinski R, Hannan E, et al.
bioRxiv
. 2025 Jan;
PMID: 39764000
The Rac1 P29S hotspot mutation in cutaneous melanoma is associated with resistance to MAPK pathway inhibitors (MAPKi) and worse clinical outcomes. Moreover, activation of Rac1 guanine exchange factors (GEFs) also...
2.
Croushore E, Stipp C, Gordon D
Int J Mol Sci
. 2024 Aug;
25(16).
PMID: 39201282
Ribonucleotide reductase (RNR) is the rate-limiting enzyme in the synthesis of deoxyribonucleotides and the target of multiple chemotherapy drugs, including gemcitabine. We previously identified that inhibition of RNR in Ewing...
3.
Herndon M, Ayers M, Gibson-Corley K, Wendt M, Wallrath L, Henry M, et al.
Dis Model Mech
. 2024 Aug;
17(9).
PMID: 39104192
Epithelial-mesenchymal transitions (EMTs) are thought to promote metastasis via downregulation of E-cadherin (also known as Cdh1) and upregulation of mesenchymal markers such as N-cadherin (Cdh2) and vimentin (Vim). Contrary to...
4.
Chen J, Ding Y, Jiang C, Qu R, Wren J, Georgescu C, et al.
Circ Res
. 2024 Apr;
134(10):1330-1347.
PMID: 38557119
Background: Tetraspanin CD151 is highly expressed in endothelia and reinforces cell adhesion, but its role in vascular inflammation remains largely unknown. Methods: In vitro molecular and cellular biological analyses on...
5.
Schillo J, Feddersen C, Peplinski R, Powell L, Varzavand A, Stipp C, et al.
NAR Cancer
. 2024 Jan;
6(1):zcad061.
PMID: 38213996
The evolution of therapeutic resistance is a major obstacle to the success of targeted oncology drugs. While both inter- and intratumoral heterogeneity limit our ability to detect resistant subpopulations that...
6.
Marchal M, Moose D, Varzavand A, Jordan N, Taylor D, Tanas M, et al.
Front Oncol
. 2023 Sep;
13:1241056.
PMID: 37746268
Introduction: Abl family kinases function as proto-oncogenes in various leukemias, and pro-tumor functions have been discovered for Abl kinases in many solid tumors as well. However, a growing body of...
7.
Zhu E, Riordan J, Vanneste M, Henry M, Stipp C, Dupuy A
NPJ Precis Oncol
. 2022 Oct;
6(1):74.
PMID: 36271142
Rare gain-of-function mutations in RAC1 drive drug resistance to targeted BRAF inhibition in cutaneous melanoma. Here, we show that wildtype RAC1 is a critical driver of growth and drug resistance,...
8.
Brockman Q, Scherer A, McGivney G, Gutierrez W, Voigt A, Isaacson A, et al.
JCI Insight
. 2022 Sep;
7(20).
PMID: 36066973
The histone methyltransferase PRC2 plays a complex role in cancer. Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas with frequent loss-of-function mutations in PRC2 that are associated with poor...
9.
Vanneste M, Feddersen C, Varzavand A, Zhu E, Foley T, Zhao L, et al.
Front Oncol
. 2020 Apr;
10:442.
PMID: 32346533
Patients with malignant melanoma have a 5-year survival rate of only 15-20% once the tumor has metastasized to distant tissues. While MAP kinase pathway inhibitors (MAPKi) are initially effective for...
10.
Moose D, Krog B, Kim T, Zhao L, Williams-Perez S, Burke G, et al.
Cell Rep
. 2020 Mar;
30(11):3864-3874.e6.
PMID: 32187555
During metastasis, cancer cells are exposed to potentially destructive hemodynamic forces including fluid shear stress (FSS) while en route to distant sites. However, prior work indicates that cancer cells are...